Solana

Solana Equity

The The Equity of Solana (HSDT) as of Oct 24, 2026 is 300.91 M USD. In the previous year, The Equity was 1.06 M USD — a change of 28,314.83% (higher).

Equity

300.91 MUSD

YoY

28,314.83%

Last updated:

In 2025, Solana's equity was 300.91 M USD, a 28,314.83% increase from the 1.06 M USD equity in the previous year.

The Solana Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
9.85 M USD
Jan 1, 2019
5.84 M USD
Jan 1, 2020
3.87 M USD
Jan 1, 2021
11.26 M USD
Jan 1, 2022
8.15 M USD
Jan 1, 2023
2.35 M USD
Jan 1, 2024
1.06 M USD
Jan 1, 2025
300.91 M USD
The Solana Equity history
YEAREquityYoY
300.91 MUSD+28,314.83%
1.06 MUSD-54.94%
2.35 MUSD-71.17%
8.15 MUSD-27.59%
11.26 MUSD+190.78%
3.87 MUSD-33.66%
5.84 MUSD-40.79%
9.85 MUSD-231.56%
-7.49 MUSD+46,154.55%
-16,193.00USD+0.01%
-16,192.00USD-98.96%
-1.56 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Solana Stock analysis

What does Solana do? Helius Medical Technologies develops and markets the PoNS device, a portable neuromodulation stimulator for neurological wellness. The company focuses on non-invasive platform technologies that enhance the brain's healing ability. The PoNS device is authorized as a class II medical device in Canada for short-term treatment of chronic balance deficits caused by mild-to-moderate traumatic brain injury, used alongside physical therapy. It delivers non-invasive neurostimulation to the tongue to induce neuromodulation. Helius Medical Technologies targets healthcare providers and rehabilitation centers that treat patients with traumatic brain injury. The company's product is designed for use in clinical settings under professional guidance, specifically for patients requiring short-term balance deficit therapy. The PoNS device is positioned as a complementary treatment within physical therapy protocols for neurological rehabilitation. The firm's revenue model is based on the sale of the PoNS device to healthcare institutions and rehabilitation facilities. These institutions purchase the device for use in their treatment programs, leveraging its non-invasive neurostimulation technology to address balance deficits in patients with mild-to-moderate traumatic brain injury. The company's focus on neurological wellness through non-invasive solutions drives its commercial strategy. Solana is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Solana's Equity

Solana's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Solana's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Solana's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Solana's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Solana’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Solana stock

The Equity of Solana is 300.91 M USD in 2025.

The Equity of Solana changed from 1.06 M USD to 300.91 M USD, representing a 28,314.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Solana since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Solana historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Solana

All Key Metrics — Solana